Roles for BlyS family members in meeting the distinct homeostatic demands of innate and adaptive B cells

Vishal J. Sindhava, Jean L. Scholz and Michael P. Cancro*

Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

INTRODUCTION
Immunologic activities are frequently categorized as either innate or adaptive, based largely upon the nature of activating receptors and subsequent effector activity. Classically, innate immune cells such as macrophages and dendritic cells use germline encoded pattern recognition receptors (PRRs) to sense threats. These PRRs interact with conserved, widely distributed microbial structures dubbed pathogen-associated molecular patterns (PAMPs; Gordon, 2002). Thus, innate responses provide immediate but broadly targeted effector functions, reflecting the comparatively limited array of invariable PRRs. In contrast, the T- and B-lymphocytes involved in adaptive responses express diverse repertoires of antigen recognition receptors generated through gene rearrangement and point mutation, yielding more precisely tailored, pathogen-specific immune responses.

These broad classifications, originally stemming from competing theories of immune cognition forwarded by Metchnikoff and Ehrlich, continue to evolve and remain robust conceptual constructs. Nonetheless, mounting evidence challenges such simplistic binary categorization, suggesting instead that cells of the mammalian immune system use a continuum of evolutionarily conserved versus somatically variant receptors, each with distinct developmental, anatomic, and functional characteristics (Herzenberg, 1989; Hirano et al., 2011; Mold and McCune, 2011). Within the B lymphoid lineage, this view is exemplified by the existence of two major developmental populations, B-1 and B-2. While both use somatically generated immunoglobulin (Ig) antigen recognition receptors, they arise from different progenitors, differ in receptor diversity, occupy distinct anatomic niches, and have divergent functions.

As detailed below, these differences suggest that B-1 cells primarily employ an evolutionarily conserved, anticipatory receptor array, are restricted to particular anatomic sites, and target a limited and relatively constant array of self and microbial epitopes. Reflecting these attributes, appropriate B-1 function can be accommodated through the establishment of a small, fixed pool with self-renewal capacity. In contrast, the B-2 pool is primarily tasked with systemic surveillance for unpredictable microbial pathogen variants, thus requiring a large pool size and the continuous turnover of an extensive potential antigen receptor array. These fundamental distinctions pose vastly different requisites for the homeostatic mechanisms governing pool size and composition.

The last decade has witnessed a growing appreciation for how the B lymphocyte stimulator (BlyS, a.k.a. B cell activating factor of the tumour-necrosis-factor family [BAFF]) family of ligands and receptors governs selection and homeostasis, particularly among B-2s and antibody-forming cells (AFCs) derived from either B-1 or B-2 ancestors. These observations prompt the question of whether this molecular family plays analogous roles in the B-1 lineage, and how the unique homeostatic demands of the B-1 niche are accommodated independently of B-2 and AFC niches. Herein we discuss key features of these two B cell populations relevant to their homeostatic requisites, review current knowledge of how the BlyS family governs homeostasis in the B-2 compartment, and consider potential BlyS family member roles in the B-1 compartment. We focus on murine B cell populations, because of the wealth of data afforded by in vivo experimental systems, but include information about human B cells as well.

DEVELOPMENT AND RECEPTOR DIVERSITY IN B LINEAGE POOLS

The B-1 and B-2 cell populations differ in terms of their developmental kinetics as well as antigen receptor repertoires. Two hypotheses have been proposed for the development of B-1 versus B-2 pools. The “separate” lineage model postulates distinct, developmentally restricted B-1 and B-2 progenitors, whereas within the “selection” model the two pools share a common progenitor and...
diverge following ligand-driven selection (reviewed in Montecino-Rodriguez and Dorshkind, 2006). In mice, B-1 cells are generated from fetal liver precursors, and proportionally predominate during fetal and early neonatal development (Hayakawa et al., 1983; Carsetti et al., 2004; Montecino-Rodriguez and Dorshkind, 2006; Montecino-Rodriguez et al., 2006; Yoshimoto et al., 2011). Once established, B-1 B cells undergo self-renewal in the periphery (Deenen and Kroese, 1995; Kantor and Herzenberg, 1993; Pastelli et al., 2003; Ghosh et al., 2011; Yoshimoto et al., 2011). There is mounting evidence that B-1 cells may continue to be produced in adult bone marrow (BM), but with greatly reduced frequency compared to B-2 cell production (Montecino-Rodriguez and Dorshkind, 2006, 2011; Montecino-Rodriguez et al., 2006; Yoshimoto et al., 2011). This early burst of production, followed by self-renewal and/or an ongoing but low rate of B-1 cell differentiation, yields a steady-state B-1 cell pool of comparatively small magnitude (a few million cells per adult mouse; Hayakawa et al., 1986; Lasek et al., 1988, Hamilton et al., 1994). Most current models for peripheral B-1 maturation involve passage through transitional, intermediate developmental stages followed by differentiation to B-1a and B-1b subsets in serous cavities (reviewed in Montecino-Rodriguez and Dorshkind, 2006, 2012; Casola, 2007). In contrast, B-2 B cells are generated primarily in BM following birth, and continue to be produced through the lifetime of the individual (Kantor and Herzenberg, 1993; Carsetti et al., 2004; Ghosh et al., 2011). Constant B-2 cell production, coupled with a relatively long average half-life, yields numbers that achieve steady-state at 8 weeks of age, eclipsing the B-1 pool in overall magnitude (tens of millions of cells per adult mouse; Hayakawa et al., 1983, 1986; Cancro, 2004a).

Both subsets use recombination activating gene (RAG)-mediated somatic recombination of Ig gene segments for antigen receptor expression (Shinkai et al., 1992; Qin et al., 1999). However, the B-1 lineage differs in two key respects. First, their B cell receptors (BCRs) tend to be skewed toward using the smaller, highly conserved J-proximal VH gene segments, such as the murine VH-11 family (Pennell et al., 1989; Pennell, 1995; Seidl et al., 1997, 1999; Herzenberg et al., 2000). Second, their fatally derived progenitors do not engage in N- or P-nucleotide additions, and thus lack appreciable juncional diversity (Gu et al., 1999, Kantor et al., 1997; Lipsanen et al., 1997). Moreover, because they rarely participate in germinal center (GC) reactions engendered by cognate T cell help, their Ig genes rarely undergo somatic hypermutation and only limited isotype switching (Berland and dered by cognate T cell help, their Ig genes rarely undergo somatic hypermutation and only limited isotype switching (Berland and Derfler, 2010). Moreover, because B-1 cells may be poised to enter cell cycle (Pastelli et al., 2003). Consistent with observations in mice, human B-1 cells spontaneously secrete IgM and show tonic intracellular signaling (Griffin et al., 2011). These observations may begin to explain why peritoneal B-1 cells can proliferate rapidly, sometimes in the absence of BCR-mediated signaling. B-2 cells, on the other hand, participate in inducible responses that often involve T cell help and further receptor diversification through somatic hypermutation of Ig genes within GCs (Chan and Brink, 2012; Victora and Nussenzweig, 2012). In these structures, successive mutation and selection processes culminate in B cells with greatly improved antigen affinity, and class switch recombination leads to Abs of various isotypes, predominantly IgG (Chan and Brink, 2012; Victora and Nussenzweig, 2012). These cells may further differentiate and join long-lived antibody-secreting cell (ASC) or memory B cell subsets (Victora and Nussenzweig, 2012). B-2 B cells are thus the ultimate “source” of the majority of high-affinity and high-affinity, pathogen-targeted Abs. MZ B cells, similar to B-1 cells, have a restricted VH repertoire, are recruited into early immune responses upon antigen activation, and can rapidly differentiate to ASCs without cognate T cell help (Martin et al., 2001; Martin and Kearney, 2002). MZ B cells may also participate in T
cell-dependent (TD) GC responses, undergo somatic hypermutation, and differentiate into memory cells (Song and Cerny, 2003; Phan et al., 2003).

In accord with their barrier and housekeeping roles, B-1 cells tend to be localized in particular anatomic niches, especially coelomic caviities and mucosal interfaces (Kroese et al., 1992), and though they can circulate, they are rare in spleen and lymph nodes (Kroese et al., 1992; Montecino-Rodriguez and Dorshkind, 2006). In contrast, the bulk of B-2 cells (members of the FO subset) form quasicentric recirculating pools, and in any given response, use only a small (∼1/100,000) proportion of available receptors (Cancro et al., 1978).MZ B cells do not recirculate in mice, but their microanatomical location at the splenic red and white pulp border makes them the first B cells to encounter blood-borne pathogens (Martin et al., 2001; Belperron et al., 2007; Kearney, 2008).

An exhaustive analysis of B-1a, B-1b, and B-2 cells from the murine peritoneal cavity indicates that selective pressures in the periphery, particularly in certain anatomic locales, further shape the repertoires of all of these B cell subsets (Vale et al., 2010). For example, cells of all of these subsets that have undergone N-addition share many similarities in repertoire, including enrichment for adult BM CDR3 sequences. This supports both the hypothesis of different developmental origins as well as a mechanism of BCR-influenced selection as factors that shape B-1 and B-2 subset repertoires, and make the peritoneal cavity – or other anatomic locales – more specialized in terms of the antigens recognized and immune responses undertaken (Montecino-Rodriguez and Dorshkind, 2006).

These differences in the generation, repertoire diversification, anatomical location, and immunological function of B-1 and B-2 populations suggest that cells of the B-1 and B-2 lineages have very different homeostatic requisites. The smaller, self-renewing B-1 population, with its relatively limited and static receptor array, is positioned to make sustained and commonly required antibody responses – including to evolutionarily “predictable” microorganisms such as endosymbionts. Continual production of B-2 cells yields a very large and qualitatively diverse B-2 population: more BLyS equates with higher absolute numbers of FO and MZ B cells (Moore et al., 1999; Hsu et al., 2002; Stohl et al., 2005). BLyS is expressed by monocytes, macrophages, dendritic cells, and neutrophils, but not by B cells themselves (Moore et al., 1999; Kawasaki et al., 2002; Litinskiy et al., 2002; Gorelik et al., 2002; Scapini et al., 2003). However, the major source of systemic BLyS is likely radiation-resistant stromal cells of secondary lymphoid organs; thus linking BLyS amounts to body volume and consistent with the observation that larger animals have more B cells than smaller ones (Gorelik et al., 2003). BLyS is a 285-amino acid type II transmembrane protein, which is cleaved at a furin consensus site and released as a soluble trimeric ligand (Moore et al., 1999; Schneider et al., 1999). Both the trimer and a 60-mer structure (composed of 20 trimers) are detected in serum and appear to be biologically active. For example, the BLyS trimer binds with highest affinity to BR3, whereas BLyS 60-mers are the more efficient TACI agonist (Boussen et al., 2008).

Unlike BLyS, APRIL has no effect on primary B-2 cell numbers (Castigli et al., 2004; Varfolomeev et al., 2004). This may reflect redundancy with BLyS, and/or roles for APRIL among antigen-experienced B cell subsets, as discussed further below. APRIL is expressed by monocytes, dendritic cells, macrophages, T cells, eosinophils, osteoclasts, and BM stromal cells (Habne et al., 1998; Mukhopadhyay et al., 1999; Nardelli et al., 2001; Litinskiy et al., 2002; Moreaux et al., 2005; Chu et al., 2011). APRIL is a 250-amino acid type II transmembrane protein processed within the Golgi apparatus by furin convertase and released as a trimeric bio logically active form; it does not form soluble 60-mers like BLyS (Lopez-Fraga et al., 2001). However, an intergenic splicing between tweek and april genes generates TWE-PRIL protein, which may exist as a membrane bound form (Praetel-Balade et al., 2002). Homeostasis of the mature naïve B-2 compartment is governed by the BLyS–BR3 axis (reviewed in Crowley et al., 2008; Table 1). BLyS–BR3 signaling integrates BCR-mediated negative selection at the transitional developmental checkpoint with homeostasis of the mature naive compartment. BLyS is a limiting survival factor, and only those cells that successfully compete for it persist in the FO or MZ B cell pools. If BLyS levels are reduced or BR3 signaling is abrogated, fewer cells survive the transitional checkpoint, and numbers of FO and MZ B cells are reduced or, in the case of BLyS knockouts, virtually non-existent (Miller and Hayes, 1991; Lentz et al., 1996; Gross et al., 2001; Schiemann et al., 2001; Castigli et al., 2004; Belnoue et al., 2008). BLyS binds to three receptors: BLyS receptor 3 (BR3; also known as BAFF-R), transmembrane activator-1 and calcium modulator and cyclophilin ligand-interactor (TACI), and B cell maturation antigen (BCMA). In contrast, APRIL binds to TACI and BCMA (Cancro, 2004b; Bossen and Schneider, 2006), and to heparan sulfate proteoglycans (HSPGs; Hendriks et al., 2003; Ingold et al., 2005). These relationships are summarized in Figure 1A. Known or potential roles (indicated by a question mark) of various receptor-ligand combinations discussed in this review are outlined in Table 1.

BLyS is the biological metric of space for the pre-immune B-2 cell pool: more BLyS equates with higher absolute numbers of FO and MZ B cells (Moore et al., 1999; Hsu et al., 2002; Stohl et al., 2005). BLyS is expressed by monocytes, macrophages, dendritic cells, and neutrophils, but not by B cells themselves (Moore et al., 1999; Kawasaki et al., 2002; Litinskiy et al., 2002; Gorelik et al., 2002; Scapini et al., 2003). However, the major source of systemic BLyS is likely radiation-resistant stromal cells of secondary lymphoid organs; thus linking BLyS amounts to body volume and consistent with the observation that larger animals have more B cells than smaller ones (Gorelik et al., 2003). BLyS is a 285-amino acid type II transmembrane protein, which is cleaved at a furin consensus site and released as a soluble trimeric ligand (Moore et al., 1999; Schneider et al., 1999). Both the trimer and a 60-mer structure (composed of 20 trimers) are detected in serum and appear to be biologically active. For example, the BLyS trimer binds with highest affinity to BR3, whereas BLyS 60-mers are the more efficient TACI agonist (Boussen et al., 2008).

Unlike BLyS, APRIL has no effect on primary B-2 cell numbers (Castigli et al., 2004; Varfolomeev et al., 2004). This may reflect redundancy with BLyS, and/or roles for APRIL among antigen-experienced B cell subsets, as discussed further below. APRIL is expressed by monocytes, dendritic cells, macrophages, T cells, eosinophils, osteoclasts, and BM stromal cells (Habne et al., 1998; Mukhopadhyay et al., 1999; Nardelli et al., 2001; Litinskiy et al., 2002; Moreaux et al., 2005; Chu et al., 2011). APRIL is a 250-amino acid type II transmembrane protein processed within the Golgi apparatus by furin convertase and released as a trimeric bio logically active form; it does not form soluble 60-mers like BLyS (Lopez-Fraga et al., 2001). However, an intergenic splicing between tweek and april genes generates TWE-PRIL protein, which may exist as a membrane bound form (Praetel-Balade et al., 2002).

Homeostasis of the mature naïve B-2 compartment is governed by the BLyS–BR3 axis (reviewed in Crowley et al., 2008; Table 1). BLyS–BR3 signaling integrates BCR-mediated negative selection at the transitional developmental checkpoint with homeostasis of the mature naive compartment. BLyS is a limiting survival factor, and only those cells that successfully compete for it persist in the FO or MZ B cell pools. If BLyS levels are reduced or BR3 signaling is abrogated, fewer cells survive the transitional checkpoint, and numbers of FO and MZ B cells are reduced or, in the case of BLyS knockouts, virtually non-existent (Miller and Hayes, 1991; Lentz et al., 1996; Gross et al., 2001; Schiemann et al., 2001; Thompson et al., 2001; Yan et al., 2001). Conversely, if BLyS levels are experimentally elevated, the stringency of transitional selection is “relaxed,” and cells that would normally be selected against – such as those with autoreactive BCRs – instead survive to join the FO or MZ pool (Stohl, 2005; Stohl et al., 2005). Numbers of cells in each of these subsets are correspondingly increased (Hsu et al., 2002). Thus, the BLyS–BR3 axis also plays a key role in peripheral tolerance (Stohl, 2005; Stohl et al., 2005). The number...
of B cells reaches several million (MZ) or tens of millions (FO) in the adult mouse. These cells are quiescent and reside in the compartment for the duration of their lifespan (measured in months) unless they respond to antigen. Thus, the developing B-2 lineage yields a mature naive compartment of sufficient steady-state size and diversity for effective immune surveillance, along with sufficient quality to avoid auto-reactivity. Mounting evidence indicates that the BLyS–BR3 axis governs primary B cell homeostasis in humans as well: naïve mature human B cells express BR3 and bind BLyS; people with a homozygous BR3 deletion have few mature B cells; and mature naïve B cells are ablated with anti-BLyS therapy (belimumab; Carter et al., 2005; Darce et al., 2007a,b; Palanichamy et al., 2009; Warnatz et al., 2009; Calero et al., 2010). Members of the BLyS family also play roles in humoral immune responses undertaken by B-2 B cells in both mice and humans. BLyS is essential for humoral immune responses in mice, as blocking BLyS signaling leads to significantly impaired TD and T cell-independent (TI) immune responses (Gross et al., 2001; Schiemann et al., 2001; Vora et al., 2003; Scholz et al., 2008). APRIL is also suggested to have roles in immune responses. For example, APRIL transgenics show significantly elevated antigen-specific IgM and IgG in response to a TI type 2 antigen (Stein et al., 2002), and APRIL plays a key role in IgA class switch and the IgA antibody response to mucosal and TI type 1 antigens (Castigli et al., 2004). Knockout mice show TACI is the BLyS family receptor important for APRIL-mediated IgA class switching (Castigli et al., 2004; Sakurai et al., 2007), though other work shows that the BLyS–TACI interaction also mediates isotype switch (Castigli et al., 2005). In vitro studies indicate that APRIL synergizes with BCR cross-linking to induce B cell proliferation, and also induces the upregulation of co-stimulatory molecules and the antigen presentation function of B cells (Yu et al., 2000; Yang et al., 2005). Either BlyS or APRIL (with other appropriate cytokines) elicits TI-like class switching in cultured human B cells (Litinskiy et al., 2002). Interestingly, a range of mutations in TACI is associated with common variable immune deficiency (CVID) and IgA deficiency (Castigli et al., 2007; Lobito et al., 2011; Martinez-Gallo et al., 2013). Furthermore, there is increasing evidence in both mice and humans that TI responses to many innate-like antigens occur through pathways that integrate BLyS or APRIL signaling through TACI with Toll-like receptor (TLR) signaling (He et al., 2010; Oropallo et al., 2011). Heparan sulfate proteoglycans have been identified as an APRIL-specific binding receptor on both B-1 and B-2 cells (Hendriks et al., 2005; Ingold et al., 2005). APRIL contains a short, basic amino acid sequence that is absent in BlyS; in association with additional basic residues these are required for APRIL binding to negatively charged HSPGs. Crystal structures reveal that the HSPG binding site of APRIL is clearly distinct from that of TACI and BCMA; and APRIL binding to HSPG is not inhibited by BCMA:Fc (Wallweber et al., 2004; Hendriks et al., 2005; Ingold et al., 2005). HSPG-mediated binding of APRIL is essential for B cell proliferation and IgA production in collaboration with TACI (Sakurai et al., 2007), raising the possibility of ternary complex formation...
### Table 1 | Roles for cytokine-receptor signals in murine B cell homeostasis.

| APRIL | BLyS |
|-------|------|
| • Translational selection | • Transitional selection |
| (Ho et al., 2002; Crowley et al., 2008; Stohl et al., 2011) | (Hsu et al., 2002; Crowley et al., 2008; Stohl et al., 2011) |
| • FO, MZ survival | • FO, MZ survival |
| (Lentz et al., 1996; Gross et al., 2001; Ho et al., 2002) | (Lentz et al., 1996; Gross et al., 2001; Ho et al., 2002) |
| • GC evolution | • GC evolution |
| (Schiemann et al., 2001; Rahman et al., 2003; Vora et al., 2003) | (Schiemann et al., 2001; Rahman et al., 2003; Vora et al., 2003) |
| • TLR/BCR crosstalk, regulation? | • TLR/BCR crosstalk, regulation? |
| (He et al., 2010; Oropallo et al., 2011) | (He et al., 2010; Oropallo et al., 2011) |
| • B-1 maintenance in spleen? | • B-1 maintenance in spleen? |
| (Lentz et al., 1996; Ng et al., 2006; Scholz et al., 2008; Mackay et al., 2010) | (Lentz et al., 1996; Ng et al., 2006; Scholz et al., 2008; Mackay et al., 2010) |
| • Class switch | • Class switch |
| (Litinskiy et al., 2002; Castigli et al., 2005) | (Litinskiy et al., 2002; Castigli et al., 2005) |
| • B-1 maintenance in spleen? | • B-1 maintenance in spleen? |
| (Lentz et al., 1996; Ng et al., 2006; Scholz et al., 2008; Mackay et al., 2010) | (Lentz et al., 1996; Ng et al., 2006; Scholz et al., 2008; Mackay et al., 2010) |
| • Integration of TLR signals? | • Integration of TLR signals? |
| (Castigli et al., 2005; Yang et al., 2009) | (Castigli et al., 2005; Yang et al., 2009) |
| • IgA class switch, B-2 and B-1 cells | • IgA class switch, B-2 and B-1 cells |
| (Litinskiy et al., 2002; Stein et al., 2002; Castigli et al., 2004; Sakurai et al., 2007; Kataoka et al., 2011) | (Litinskiy et al., 2002; Stein et al., 2002; Castigli et al., 2004; Sakurai et al., 2007; Kataoka et al., 2011) |
| • Short-lived ASC responses | • Short-lived ASC responses |
| (Litinskiy et al., 2002; He et al., 2010; Oropallo et al., 2011) | (Litinskiy et al., 2002; He et al., 2010; Oropallo et al., 2011) |
| • Class switch | • Class switch |
| (Litinskiy et al., 2002; Stein et al., 2002; Castigli et al., 2004; Sakurai et al., 2007; Kataoka et al., 2011) | (Litinskiy et al., 2002; Stein et al., 2002; Castigli et al., 2004; Sakurai et al., 2007; Kataoka et al., 2011) |
| • IgA class switch | • IgA class switch |
| (Litinskiy et al., 2002; Stein et al., 2002; Castigli et al., 2004; Sakurai et al., 2007; Kataoka et al., 2011) | (Litinskiy et al., 2002; Stein et al., 2002; Castigli et al., 2004; Sakurai et al., 2007; Kataoka et al., 2011) |
| • Plasma cell survival | • Long-lived plasma cell generation and/or maintenance |
| (Reijmers et al., 2011) | (Reijmers et al., 2011) |
| • B-1 maintenance in the peritoneum? | • B-1 maintenance in the peritoneum? |
| (Gross et al., 2001; Shulga-Morskaya et al., 2006) | (Gross et al., 2001; Shulga-Morskaya et al., 2006) |
| • APRIL-HSPG-TACI signaling? | • APRIL-HSPG-TACI signaling? |
| (Sakurai et al., 2007; Kimberley et al., 2009) | (Sakurai et al., 2007; Kimberley et al., 2009) |
| • Long-lived plasma cell homing to or maintenance in BM | • Long-lived plasma cell homing to or maintenance in BM |
| (O’Connor et al., 2004; Inghold et al., 2005; Benson et al., 2008) | (O’Connor et al., 2004; Inghold et al., 2005; Benson et al., 2008) |
| • Memory B cell recall response? | • Memory B cell recall response? |
| (Avery et al., 2003; Darce et al., 2007; Ettinger et al., 2007; Scholz et al., 2008) | (Avery et al., 2003; Darce et al., 2007; Ettinger et al., 2007; Scholz et al., 2008) |
| • B cell maturation | • B cell maturation |
| (Reijmers et al., 2011) | (Reijmers et al., 2011) |
| • IgA class switch | • IgA class switch |
| (Sakurai et al., 2007) | (Sakurai et al., 2007) |
| • Plasma cell survival | • Plasma cell survival |
| (Reijmers et al., 2011) | (Reijmers et al., 2011) |
| • B-1 maintenance in the peritoneum? | • B-1 maintenance in the peritoneum? |
| (Gross et al., 2001; Shulga-Morskaya et al., 2006) | (Gross et al., 2001; Shulga-Morskaya et al., 2006) |

In this regard, a study by Kimberley et al. (2009) showed that HSPG serves as a platform for APRIL multimerization on the cell surface, which can then signal through TACI for optimal activation of B cells. Central to these events is an interplay between APRIL–TACI–HSPG. In this regard, a study by Kimberley et al. (2009) showed that HSPG serves as a platform for APRIL multimerization on the cell surface, which can then signal through TACI for optimal activation of B cells. Germinal centers, a hallmark of T cell immune responses, generate high-affinity, class-switched antibody as well as persistent (long-lived) plasma cells and memory B cells (Victora and Nussenzweig, 2012). GCs begin in the absence of BLyS or BR3, but are not maintained—likely reflecting the paucity of naive B cells available for recruitment into the ongoing GC reaction, but also suggesting a role for BLyS- or BR3 signaling in GC evolution (Rahman et al., 2003; Vora et al., 2003). Likewise, high-affinity, class-switched antibody responses are significantly reduced, and the memory response is impaired (Schiemann et al., 2001). Studies of APRIL knockouts in different genetic backgrounds report disparate effects upon T cell antigen challenge: either a normal humoral response, or enlarged GCs and an enhanced IgG response (Castigli et al., 2004; Varfolomeev et al., 2004). There is increasing evidence that both BLyS and APRIL are required for plasma cell generation and maintenance (Inghold et al., 2005; Benson et al., 2008), and that APRIL is important for plasma cell homing to or retention in the BM (Inghold et al., 2005; Belnoue et al., 2008). Studies of BCMA knockouts show that this receptor is critical for maintenance of long-lived plasma cells in BM (O’Connor et al., 2004). In addition, HSPGs are key for APRIL-mediated plasma cell survival (Reijmers et al., 2011). Memory B cells appear to occupy a BLyS-independent homeostatic niche in mice. Neither BLyS nor APRIL is required for
memory B cell maintenance in mice treated with anti-BLyS, BR3-Ig, or TACI-Ig, though unw switch (IgM) memory cells are less resistant to BLyS neutralization (Benson et al., 2006; Scholz et al., 2008). In contrast, BLyS promotes survival of resting human memory B cells and plasmablasts (Avery et al., 2003; Ettinger et al., 2007; Karnell and Ettinger, 2012). BLyS treatment of human memory B cells (CD27+ in vitro) attenuates ASC formation with TDF-like stimulation but enhances ASC formation with TDF-like stimulation (Darce et al., 2007a), and activated cells upregulate BCMA (Darce et al., 2007b), again pointing to roles for BLyS family members in human plasma cell differentiation. BCMA and/or TACI expression have been reported on murine and human memory B cells, but elucidation of expression levels and patterns — as well as homeostatic requisites — awaits definitive characterization of memory B cell subsets (Darce et al., 2007b; Benson et al., 2008; Tomayko et al., 2010; Scholz et al., 2011).

**BLyS FAMILY MEMBERS MAY PLAY ROLES IN B-1 B CELL HOMEOSTASIS**

The molecules that govern generation, maintenance, and selection of B-1 subsets are under active investigation. However, there is increasing evidence that BLyS family members play analogous but distinct roles in B-1 and B-2 pools. Peritoneal B-1 cells of mice express both BR3 and TACI but barely detectable surface BCMA (Ng et al., 2006). Nevertheless, BR3 knockouts, BR3 signaling-mutant mice, and BLyS knockouts all have wild-type or moderately (not significantly) reduced numbers of B-1 cells in the peritoneal cavity (Lente et al., 1996; Schneider et al., 2001; Sasaki et al., 2004; Shulga-Morskaya et al., 2004; Gavin et al., 2005). BLyS-overexpressing mice show a significant increase in splenic B-1 numbers and peritoneal cavity B-1 percentages (Gavin et al., 2005), consistent with some prior reports (Gross et al., 2001), but not others indicating similarity between B-1 populations in BLyS transgenic and wild-type mice (Mackay et al., 1999). Interestingly, mice in which BLyS was neutralized had reduced splenic B-1 numbers but normal peritoneal B-1 numbers (Scholz et al., 2008), suggesting the possibility of different homeostatic requisites in different anatomic environments. There was a significant decrease in peritoneal B-1 numbers in mice transgenic for TACI-Ig, a molecule that neutralizes both BLyS and APRIL (Gross et al., 2001). In contrast, TACI-Fc transgenic mice showed only a negligible decrease in peritoneal B-1 subsets (Schneider et al., 2001). B-1 transitional cells are not dependent on BR3 signaling, although similar to B-2 transitional cells, BCRI signaling is required for survival and continued maturation (Mackay et al., 2010; Montecino-Rodriguez and Dorskind, 2008). BLyS treatment of B-1 cells stimulated with TLR ligands leads to upregulated BR3 and TACI expression, increased proliferation, and cytokine secretion (Ng et al., 2006). Together these results suggest that neither BR3 nor BLyS is absolutely necessary for B-1 cell development, selection, or survival in the periphery; though BLyS may modulate B-1 cell maintenance or responses in certain anatomic sites, for example through localized BLyS production by myeloid cells (Gavin et al., 2005; Table 1).

Clearly, peritoneal B-1 cells are far less dependent on BLyS than are B-2 cells. One possible explanation is that peritoneal B-1 cells require alternative or redundant survival factors, for example, APRIL (discussed further below). Unlike splenic B-2 cells, peritoneal B-1 cells are constitutively active with regard to surface and intracellular activation markers and spontaneous IgM secretion (Fischer et al., 2001; Kreitkramer et al., 2003; Tumang et al., 2004); and activated B cells may have different survival requisites than quiescent cells. Splenic and peritoneal B-1a cells both express CD5, but only peritoneal B-1 cells respond to PMA as shown by cell cycle progression, Ig secretion, and expression of Notch-related genes (Fischer et al., 2001; Tumang et al., 2004). As noted above, peritoneal but not splenic B-1 cells express a constitutively activated form of STAT3, which regulates IL-10 gene expression (Fischer et al., 2001). In addition, the microenvironment of the peritoneal cavity is thought to be very different from that of the spleen, and may contain redundant or alternative survival factors that can substitute for BLyS. Therefore, it is tempting to speculate that splenic and peritoneal B-1 cells are homeostatically different from each other as well as from B-2 subsets and may require different signals for survival.

Likewise, there is evidence, albeit indirect and in some cases conflicting, that APRIL may play roles in B-1 B cell maintenance or responses. Indeed, B-1 B cells express BR3 and TACI (Ng et al., 2006), and in one report, peritoneal B-1 cells expressed a higher level of TACI compared with peritoneal B-2 cells (similar to the higher level of TACI expressed by MZ B cells compared to FO B cells; Shulga-Morskaya et al., 2004; Ng et al., 2006; Stadnik et al., 2008). Nonetheless, TACI knockout mice have normal numbers of peritoneal B-1 cells (von Bulow et al., 2001). APRIL knockout mice were reported to have normal percentages of peritoneal B-1 cells (Castigli et al., 2001), yet APRIL transgenic mice had increased percentages of splenic B-1 cells (Planells et al., 2004). APRIL knockout mice also have significantly decreased serum IgA levels as well as IgA responses to orally administered antigen (Castigli et al., 2004); however, although IgA is an isotype normally associated with B-1 cells, it is not known if B-2 as well as B-1 cells were involved in these responses. There are conflicting reports of B-1 cell prevalence in mice that should have been chronically depleted of both BLyS and APRIL using soluble receptor transgenes (Gross et al., 2001; Schneider et al., 2003). The discrepancy in these observations may have been due to differences in the transgenes and expression cassettes employed; or to insufficient levels of soluble receptor for complete neutralization of both BLyS (including BLyS 60-mers) and APRIL. Ex vivo observations and cell culture experiments indicate that mucosal dendritic cells upregulate APRIL production, and B-1a cells upregulate TACI and undergo enhanced class switching to IgA in a mucosal, TI immune response (Kataoka et al., 2011), echoing roles for APRIL and TACI in TI responses of B-2 B cells. Taken together, these observations suggest potential roles for APRIL in B-1 cell survival, activation, or function, but comprehensive analyses will be required to clarify the mechanisms involved. There are several approaches that might be taken to definitively establish the role of APRIL in B-1 cell origin/maintenance, such as detailed studies of B-1 cell numbers in APRIL knockout mice, or enumeration of B-1 cells in BCMA/Fc transgenic mice or following BCMA/Fc treatment of wild-type mice. Furthermore, it will be important to examine the role of the APRIL-HSPG axis, since B-1 cells express TACI, and HSPGs can serve as a platform for...
APRIL multimerization and cross-linking with TACI (Kimberley et al., 2009).

SUMMARY

The two major B lymphocyte lineages, B-1 and B-2, together provide an array of antigen recognition receptors for “expected” and “unexpected” antigenic and non-antigenic pathogens (circulating as well as location-specific surveillance and persistence; constitutive as well as inducible Ab production; and rapid as well as long-term humoral responses). BLyS family molecules play key roles in the maturation and maintenance of B-2 B cells in the periphery, and there is increasing evidence that this same family plays similar roles for cells of the B-1 lineage. Therefore, we now include B-1 cells in our working model for BLyS-mediated homeostatic control, outlined in Figure 1B (Crowley et al., 2005, 2008; Müller et al., 2006; Trendel et al., 2006, 2009). B-1 cells are placed in the area of overlap between the “BLyS space” and the “APRIL space” based on mounting evidence that BLyS and/or APRIL mediate B-1 cell maintenance or responses in different anatomic locales. For example, a role for APRIL in B-1 survival is suggested by one report of a nearly complete absence of peritoneal B-1 cells in TACI-Ig transgenic mice, compared with the smaller or localized effects against “fimmu-04-00037” — 2013/2/22 — 15:35 — page 7 — #7

REFERENCES

Alquupalli, K. R., Leong, J. M., Wood-Belperron, A. A., Dailey, C. M., Belnoue, E., Pihlgren, M., McGaha, T. (2003). BAFF selectively engages bone marrow stromal cells. J Clin Invest 112, 286–297.

Booth, C. J., and Bockenstedt, L. K. (2005). Divide and conquer: division and poorly expressed by early-life plasmablast survival in the bone marrow. J Immunol 174, 253–300.

Bossen, C., and Schneider, P. (2006). TACI, unlike BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 52, 3945–3954.

Casola, S. (2007). Control of peripheral B-cell development. Curr Opin Immunol 19, 145–149.

Castigli, E., Scott, S., Dolevoglu, F., Bourc'h, J. A., Bhan, A. K., et al. (2004). Impaired IgA class switching and homeostasis of naive B-1 B cells. J Exp Med 197, 179–191.

Chu, V. T., Freilich, A., Steinhausser, G., Schud, T., Rock, T., Flihaut, et al. (2011). Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol 12, 151–159.

Crowley, E. E., Scholle, L. J., Quinn, W. J. III, Stadanlick, J. E., Trendel, J. J., et al. (2008). Homeostatic control of lymphocyte subsets. Immunol Rev 220, 73–85.

Crowley, E. E., Trendel, L. S., Stadanlick, J. E., Carpenito, E., and Canonico, M. P. (2005). Homeostatic immune specification among naive and activated B cells: a growing role for the BLyS family of receptors and ligands. Semin Immunol 17, 195–209.

Dacie, J. R., Arndt, B. K., Chang, S. R., and Jelinek, D. F. (2007a). Divergent effects of BAFF on human memory B-cell differentiation and plasma cells. J Immunol 178, 5612–5622.

Dacie, J. R., Arndt, B. K., Wu, X., and Jelinek, D. F. (2007b). Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 179, 2726–2736.

Deenen, G. J., and Kroese, F. G. (1993). Marginal zone B cell depletion impairs marine host defense against Yersella hurgdorferi infection. J Exp Med 175, 3533–3550.

ETTINGER, R., SIMS, G. P., ROBINSON, K., WILHAMS, D., FISCHER, B. T., GRAMMER, A. C., et al. (2007). IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a
unique population of human splenic memory B cells. J. Immunol. 179, 2872–2882.

Fischer, G. M., Sohl, L. A., Hastings, W. D., Yang, K., Gorossy, R. M., Nicholas, B. S., et al. (2001). Splenic and peripheral B cells differ in terms of transcriptional and proliferative features that separate peripheral B-1 from splenic B-2 cells. Cell Immunol. 213, 62–71.

Gartt, A. L., Dong, B., Shag, P., Atlas, A., Grass, D. W., Scott, M. L., et al. (2005). deltaf BAFF: a splice variant of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models. Proc. Natl. Acad. Sci. USA 102, 2079–2084.

Gordon, S. (2002). Pattern recognition receptors: doubling up for the innate immunoreceptor? Cell 111, 877–879.

Guilford, K., Gibbels, K., Dobole, M., Kalka, S. L., and Rethmann, T. L. (2011). Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J. Exp. Med. 198, 957–964.

Griffin, D. O., Holodick, N. E., and Gorelik, L., Gilbride, K., Dobles, M., et al. (2010). TACI-Ig neutralizes BAFF TNFsf13B polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun. 3, 424–429.

Hamilton, A. M., Lehrman, A., and Kearney, J. F. (1994). Immunodeficiency syndrome analysis of B-1 cell phenotype in the mouse. Int. Immunol. 6, 355–361.

Hart, R. R., and Harakawa, K. (2001). B cell development pathways. Annu. Rev. Immunol. 19, 905–921.

Hayakawa, K., Hardy, R. R., Perillo, D. B., and Herzenberg, L. A. (1986). Peripheral Ly-1 B cells: genetic control, autoantibody production, increased lability of light-chain expression. Eur. J. Immunol. 16, 451–456.

Hayakawa, K., Hardy, R. R., and Herzenberg, L. A. (1985). The “Ly-1” B-cell subpopulation in normal immunodeficient, and autoimmune mice. J. Exp. Med. 157, 202–215.

He, B., Santamaria, B., Xu, W., Celis, M., Chen, K., Puga, L., et al. (2010). The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptin MyD88. Nat. Immunol. 11, 830–840.

Hendrikx, J., Hankele, L., Jong-Oudding, J., Harderwijk, P., Pab, S. T., Hahne, M., et al. (2005). Human sialic acid-binding immunoglobulin-like lectin (sialoadhesin) promotes cellular immunity to virally infected cells. J. Immunol. 175, 9–22.

Hendriks, J., Planelles, L., de Jong, J., Hendriks, J., Planelles, L., de Jong, J., et al. (2005). Identification of a unique population of human splenic memory B cells. Eur. J. Immunol. 35, 252–5–13.

Hirota, M., Uno, S., Gao, J., and Cooper, M. D. (2011). The evolution of adaptive immunity in vertebrates. Adv. Immunol. 107, 125–197.

Hou, R., Huafei, H., Eichler, S. M., Linsley, P. S., Gilchrist, D. M., and Camens, P. M. (2002). Cutting edge B cells. Current knowledge of transitory and mature B cells through distinct modalities. J. Immunol. 169, 3993–3995.

Inghot, K., Zumtobel, A., Tardivel, A., Haard, R., Steiner, Q. G., Cachero, T. M., et al. (2005). Identification of proteoglycans as the APRIL-specific binding partners. J. Exp. Med. 201, 1375–1385.

Karras, J. G., Wang, X., Hsu, L., Howard, B. G., Frank, D. A., and Bethin, T. L. (1997). Signal transducer and activator of transcription-5 (SSTAT5) is constitutively activated in normal, self-renewing B cells but only inducibly expressed in conventional B lymphocytes. J. Exp. Med. 185, 1035–1044.

Kataoka, K., Fujihashi, K., Takano, Y., Gilbert, R. S., Sokol, S., Kohr, B., et al. (2011). Oral mucosal dendritic cells modulate T cell-independent IgA class switching on B-1 B cells. Proc. Natl. Acad. Sci. USA 108, 19665–19670.

Kearney, J. F. (2008). B cell subpopulations and secondary lymph organ architecture. Seven J. Immunol. 20, 1–5.

Kimberly, F. C., van Boosten, L., Cameron, K., Hardenberg, G., Marquet, J. A., Hahe, M., et al. (2009). The proteoglycan (heparan sulfate tetrasaccharide) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking. J. Biol. Chem. 253, 1584–1593.

Koscher, K., Jungheinrich, A., Stepnowski, J., Janowska-Wieczorek, A., Hoffmann, R., and Weis, S. (2003). Antibody repertoire and gene expression profile: implications for different developmental and functional traits of splenic and peritoneal B-1 lymphocytes. J. Immunol. 171, 1512–1521.

Kremer, R. J., Hakenberg, W. O., Heiberg, P. S., Balzarini, J., and Simonsen, L. (2008). Dendritic cell interaction with Toll-like receptor 4 is required for triggering through Toll-like receptor 7 in CD4+ foxP3+ regulatory T cells. J. Leukoc. Biol. 83, 167–176.

Lalor, P. A., Herzenberg, L. A., Adams, M. L., He, B., Schaffer, A., Casali, P., et al. (2002). DCs induce CD40-independent immunoglobulin class switching through APRIL and AIFR1. Nat. Immunol. 3, 802–809.

Lobov, A. A., Gabri, T. L., Mokhova, J. P., and Kimble, F. C. (2011). Diverse causing mutations in the DAF and TNFR superfamily: focus on molecular mechanisms driving disease. Trends Immunol. 32, 494–505.

Lopez-Fraga, M., Fernandez, R., Albiz, J. P., and Hahne, M. (2001). Article titled active APRIL is a secreted fol- lowing intracellular processing in the Golgi apparatus by furin convertase. EMBO Exp. Rep. 2, 945–953.

Macchione, F., Figge, W. A., Sandik, D., Lepage, M., and Hibbs, M. L. (2003). B-cell stage and contingent dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol. Rev. 227, 205–225.

MacKenzie, W. S., Sasoli, D., Lenton, P., Ambrose, C., Bathelier, M., Schindler, P., et al. (1999). Microsomal BAFF deficiency results in hyper-IgM syndrome along with autoim- mune manifestations. J. Exp. Med. 190, 1677–1710.

Martin, E., and Kearney, J. F. (2002). Marginal zone B cells. Nat. Rev. Immunol. 2, 325–335.

Martin, E., Oliver, A. M., and Kear- ney, J. F. (2001). Marginal zone and B-1 B cells unite in the early response against T-independent antigens. Immunology 14, 617–627.

Martinez-Gallo, M., Radigan, L., Almeida, M. B., Martinez-Pomar, N., Matamoros, N., and Cunningham-Rundles, C. (2013). TACI mutations and impaired B-cell function in subjects with CVID and healthy heterozygous carriers. J. Allergy Clin. Immunol. 131, 468–476.

Miller, D. J., and Hayes, C. E. (1991). Phenotypic and genetic characterization of a unique human B-lymphocyte defi- ciency in strain 6-59/79 mice. J. Immunol. 147, 1125–1130.

Miller, P. D., Stadnick, J. E., and Cance, M. P. (2000). Space, selection, and surveillance: setting boundaries with BAFF. J. Immunol. 164, 685–690.

Mold, I. E., and McCane, J. M. (2011). At the crossroads between tolerance
Sindhava et al. Homeostasis of innate/adaptive B cells

and aggression: revisiting the “lay-er-ted immune system” hypothesis. ClinicaIRE2: 35–41.
Montecino-Rodríguez, E., and Dor-
shkind, K. (2011). Formation of B-1 B cells from neonatal T-originat-
ing cells exhibits Nk-kaap-like re-
nundancy. J. Immunol. 187, 5712–
5719.
Montecino-Rodriguez, E., and Dor-
shkind, K. (2006). New perspectives in B-1 B cell development and func-
tion. Trends Immunol. 27, 428–433.
Montecino-Rodríguez, E., and Dor-
shkind, K. (2011). Formation of B-1 B cells from neonatal T-originat-
ing cells exhibits Nk-kaap-like re-
nundancy. J. Immunol. 187, 5712–
5719.

www.frontiersin.org
February 2013 | Volume 4 | Article 37 |
9
Tumang, J. R., Hastings, W. D., Bai, C., and Rothstein, T. L. (2004). Peritoneal and splenic B-1 cells are separable by phenotypic, functional, and transcriptional characteristics. Eur. J. Immunol. 34, 2158–2167.

Vale, A. M., Tanner, J. M., Schelonka, R. L., Zhang, Y., Zemlin, M., Garfall, G. L., et al. (2010). The peritoneal cavity B-2 antibody repertoire appears to reflect many of the same selective pressures that shape the B-1a and B-1b repertoires. J. Immunol. 185, 6085–6095.

Varfolomeev, E., Kloskel, F., Martin, E., Sousaungere, D., Wang, H., Lawrence, D., et al. (2004). APRIL-deficient mice have normal immune system development. J. Exp. Med. 200, 1–11.

Victora, G. D., and Nussenzweig, M. C. (2012). Germinal centers. Annu. Rev. Immunol. 30, 429–457.

von Bulow, G. U., van Deursen, J. M., and Bram, R. J. (2001). Regulation of the T-independent humoral response by TACI. Immunity 14, 573–582.

Vora, K. A., Wang, L. C., Rao, S. P., Liu, Z. Y., Mejias, G. R., Catifer, A. H., et al. (2003). Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J. Immunol. 171, 547–553.

Walker, H. J., Compaan, D. M., Staveaux, M. A., and Hymowitz, S. G. (2004). The crystal structure of a proliferation-inducing ligand. APRIL. J. Mol. Biol. 343, 283–290.

Warrate, K., Salem, L., Rizzu, M., Fischer, B., Gatenbryer, S., Bohm, I., et al. (2009). B cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc. Natl. Acad. Sci. U.S.A. 106, 16945–16950.

Warnatz, K., McManus, J., Chai, B., Lee, W. P., Hsu, B., Harless, S., et al. (2005). Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr. Biol. 11, 1547–1552.

Yang, M., Hase, H., Logsdin-Addison, D., Varughese, L., Soel, R., and Ting, A. T. (2005). B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J. Immunol. 175, 2114–2124.

Yoshimoto, M., Montecino-Rodriguez, E., Fedkowicz, M. J., Prentice, P., Shelley, W. C., Comery, S. J., et al. (2011). Embryonic day 9 yolk sac and intra-embryonic hematopoietic independently generate a B-1 and marginal zone progenitor lacking B-2 potential. Proc. Natl. Acad. Sci. U.S.A. 108, 13945–13950.

Yu, G., Boone, T., Delaney, J., Hawkins, N., Kelley, M., Kamrukkun, M., et al. (2000). APRIL and TALL-I and receptors BCMA and TACI system for regulating humoral immunity. Nat. Immunol. 1, 232–236.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.